Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 14/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 13/20 | 0.55 |
| ▸ | CCNC | P24863 | 4/20 | 0.43 |
| ▸ | CDK8 | P49336 | 4/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7791212 | 0.87 | SELE (0.65) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7255106 | 0.81 | ICAM1 (0.64) | SELEICAM1 | |
| SCHEMBL7053701 | 0.81 | ICAM1 (0.58) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7052567 | 0.81 | CDK8 (0.58) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7053173 | 0.80 | IKBKB (0.45) | SELEICAM1CDK8 | |
| SCHEMBL7797428 | 0.79 | ICAM1 (0.56) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7255489 | 0.79 | ICAM1 (0.59) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7801846 | 0.78 | CCNC (0.60) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7797355 | 0.78 | ICAM1 (0.60) | SELEICAM1CCNCCDK8VCAM1 | |
| SCHEMBL7931909 | 0.77 | ICAM1 (0.62) | SELEICAM1CCNCCDK8VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | SELE 16/4885ICAM1 1/4885CCNC 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.